Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00602667 · OUTCOME

Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma · Source last updated 2026-05-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percent Probability
Interval / dispersion
95% Confidence Interval
Time frame
From date on treatment until date of first progression or relapse or disease related death or date of last contact, estimated at 1 year after treatment

What was measured

Progression was defined as 25% increase in the size of any measurable lesion; the appearance of a new lesion; or the conversion of negative cerebrospinal fluid (CSF) cytology to positive. Defined as the time interval from date on treatment until the date of first progression, medulloblastoma-related death or date of last contact for patients who have not experienced an event. All eligible medulloblastoma patients who received any methotrexate are included in this analysis.

Analysis population: All eligible medulloblastoma patients started methotrexate and were included (n=81). PFS estimates are reported by risk group.

Groups in this outcome

Low-Risk Group

Medulloblastoma patients \<3 years of age; histological diagnosis of desmoplastic nodular (DN)/medulloblastoma with extensive nodularity (MBEN); no evidence of metastatic disease (M0); and a surgical gross total resection (GTR) or near total resection (NTR) defined as residual tumor or imaging abnormality (not definite for residual tumor) with a size of less than 1 cm\^2 on post-op computed tomography (CT) or magnetic resonance imaging (MRI) \[R0\])

Intermediate-Risk Group

Medulloblastoma patients \<3 years of age, M0, and either R0 resection with any other medullo histology other than DN/MBEN (i.e., classic or large cell anaplastic (LCA)), or with a subtotal resection (with a residual tumor or imaging abnormality with a size of \>1 cm\^2 on post-op imaging (R+), and DN/MBEN). Children 3-5 years of age were also included in this group High Risk

High-Risk Group

Medulloblastoma patients \<3 years of age with evidence of metastatic disease

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Low-Risk Group23
Intermediate-Risk Group32
High-Risk Group26

Reported measurements

Source class 1
Values in Percent Probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Low-Risk Group73.9Not reported56.591.3Not reported
Intermediate-Risk Group46.9Not reported30.263.6Not reported
High-Risk Group30.8Not reported14.147.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        56.5
        upper Limit
        91.3
        value
        73.9
      2. group Id
        OG001
        lower Limit
        30.2
        upper Limit
        63.6
        value
        46.9
      3. group Id
        OG002
        lower Limit
        14.1
        upper Limit
        47.5
        value
        30.8
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    2. group Id
      OG001
      value
      32
    3. group Id
      OG002
      value
      26
    units
    Participants
description
Progression was defined as 25% increase in the size of any measurable lesion; the appearance of a new lesion; or the conversion of negative cerebrospinal fluid (CSF) cytology to positive. Defined as the time interval from date on treatment until the date of first progression, medulloblastoma-related death or date of last contact for patients who have not experienced an event. All eligible medulloblastoma patients who received any methotrexate are included in this analysis.
dispersion Type
95% Confidence Interval
groups
  1. description
    Medulloblastoma patients \<3 years of age; histological diagnosis of desmoplastic nodular (DN)/medulloblastoma with extensive nodularity (MBEN); no evidence of metastatic disease (M0); and a surgical gross total resection (GTR) or near total resection (NTR) defined as residual tumor or imaging abnormality (not definite for residual tumor) with a size of less than 1 cm\^2 on post-op computed tomography (CT) or magnetic resonance imaging (MRI) \[R0\])
    id
    OG000
    title
    Low-Risk Group
  2. description
    Medulloblastoma patients \<3 years of age, M0, and either R0 resection with any other medullo histology other than DN/MBEN (i.e., classic or large cell anaplastic (LCA)), or with a subtotal resection (with a residual tumor or imaging abnormality with a size of \>1 cm\^2 on post-op imaging (R+), and DN/MBEN). Children 3-5 years of age were also included in this group High Risk
    id
    OG001
    title
    Intermediate-Risk Group
  3. description
    Medulloblastoma patients \<3 years of age with evidence of metastatic disease
    id
    OG002
    title
    High-Risk Group
param Type
NUMBER
population Description
All eligible medulloblastoma patients started methotrexate and were included (n=81). PFS estimates are reported by risk group.
reporting Status
POSTED
time Frame
From date on treatment until date of first progression or relapse or disease related death or date of last contact, estimated at 1 year after treatment
title
Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients
type
PRIMARY
unit Of Measure
Percent Probability

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice